Valion Bio (VBIO) EBT Growth (1y) (2022 - 2025)
Powered by 
Analysis
Valion Bio (VBIO) EBT Growth (1y) (2022 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 76.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -522.15% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 8.48% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.60% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 88.92% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.23% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 530.43% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -82.20% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -73.24% |
| Jun 30, 2025 | -45.85% |
| Mar 31, 2025 | -1.69% |
| Dec 31, 2024 | 33.91% |
| Sep 30, 2024 | 18.69% |
| Jun 30, 2024 | 37.60% |
| Mar 31, 2024 | 30.01% |
| Dec 31, 2023 | 0.53% |
| Sep 30, 2023 | 31.89% |
| Jun 30, 2023 | 29.59% |
| Mar 31, 2023 | 5.58% |
| Dec 31, 2022 | 1.57% |
| Sep 30, 2022 | -110.25% |
| Jun 30, 2022 | -136.15% |
| Mar 31, 2022 | -65.27% |